Never Too Late: If you missed the IPKat last week! Never Too Late: If you missed the IPKat last week! Reviewed by Simone Lorenzi on Wednesday, April 08, 2026 Rating: 5
Trust is not enough: German Supreme Court tightens liability for Google Ads    Trust is not enough: German Supreme Court tightens liability for Google Ads Reviewed by Marcel Pemsel on Wednesday, April 08, 2026 Rating: 5
[Book Review] Stone on European Union Design Law: A Practitioners’ Guide [Book Review] Stone on European Union Design Law: A Practitioners’ Guide Reviewed by Marcel Pemsel on Tuesday, April 07, 2026 Rating: 5
[Guest post] The TRIPS non-violation moratorium has expired: What happened in Yaoundé, and what comes next [Guest post] The TRIPS non-violation moratorium has expired: What happened in Yaoundé, and what comes next Reviewed by Eleonora Rosati on Sunday, April 05, 2026 Rating: 5
[Guest post] No cultural funding from a collecting society at its own discretion and not for unauthorised parties [Guest post] No cultural funding from a collecting society at its own discretion and not for unauthorised parties Reviewed by Eleonora Rosati on Sunday, April 05, 2026 Rating: 5

Friday Fantasies

Enjoy the Easter break with the latest news from the IP world. Events 20 - 24 April 2026: IP Transactions: Law and Practice   UCL’s Facu...
- Friday, April 03, 2026
Friday Fantasies Friday Fantasies Reviewed by Marcel Pemsel on Friday, April 03, 2026 Rating: 5
[Guest Post] The WTO's Tale of Two Dispute Systems [Guest Post] The WTO's Tale of Two Dispute Systems Reviewed by Jocelyn Bosse on Thursday, April 02, 2026 Rating: 5
Never too late: If you missed The IPKat last week! Never too late: If you missed The IPKat last week! Reviewed by Wissam Bentazar on Wednesday, April 01, 2026 Rating: 5

Sunday Surprises

Dear Gentle Readers, here is your weekly summary of IP news, events, opportunities (and gossip) gathered by the Kats!  Latest news Gema vers...
- Sunday, March 29, 2026
Sunday Surprises Sunday Surprises Reviewed by Dr Rose Hughes on Sunday, March 29, 2026 Rating: 5
Patenting stem cell therapies in the US: The role and risks of product-by-process claims (Restem v Jadi cell) Patenting stem cell therapies in the US: The role and risks of product-by-process claims (Restem v Jadi cell) Reviewed by Dr Rose Hughes on Sunday, March 29, 2026 Rating: 5
Powered by Blogger.